Converge Bio is accelerating drug development through GenAI-powered innovations in discovery, molecule design and manufacturing to create the therapies of tomorrow, today.
Location: United States
Total raised: $30.5M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.01.2026 | Series A | $25M | Bessemer V... |
| 22.11.2024 | - | $5.5M | - |
Mentions in press and media 10
| Date | Title | Description |
| 15.01.2026 | Converge Bio Ignites AI Drug Discovery with $25M Investment | Converge Bio secured $25 million in Series A funding, bringing total capital to $30 million. This propels its generative AI platform, transforming drug discovery. The company deploys integrated AI systems, not just models, directly into R&a... |
| 13.01.2026 | Converge Bio Receives $25M Series A Round | BOSTON, MA, Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding, bringing its total raised to $30 million. >> Click here for more funding data on Converge Bio ... |
| 13.01.2026 | Converge Bio Lands $25M to Replace Trial-and-Error Drug Discovery | Converge Bio Team What You Should Know – Converge Bio has announced a $25M Series A funding round led by Bessemer Venture Partners, bringing its total raised to $30M. – Moving beyond the “AI promise” gap, the company provides end-to-end AI ... |
| 13.01.2026 | Converge Bio raises $25M to accelerate drug discovery using generative AI solutions Send us a News Tip EXTRACT THE SIGNAL FROM THE NOISE Cookies | Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in early-stage funding to develop better drugs for pharmaceutical companies and open up opportunities in the industry using arti... |
| 13.01.2026 | Converge Bio Raises $25M in Series A Funding | Converge Bio, a Boston, MA-based provider of an AI platform for accelerated drug discovery and development, raised $25M in Series A funding. The round was led by Bessemer Venture Partners, with participation from TLV Partners, Vintage Inves... |
| 22.11.2024 | Converge Bio: The Future of Drug Discovery Speaks the Language of Life | In the world of pharmaceuticals, time is a luxury few can afford. The process of drug discovery is a labyrinthine journey, often taking a decade or more, with costs spiraling past a billion dollars. Yet, a new player has entered the arena, ... |
| 22.11.2024 | Converge Bio raises $5.5M to expedite drug discovery, development with GenAI | Photo: mediaphotos/Getty Images Converge Bio has raised $5.5 million in seed funding led by TLV Partners. WHAT IT DOES Converge Bio is a generative AI hub for Biotech and Pharma that allows the accelerated discovery and development of drugs... |
| 21.11.2024 | Converge Bio Raises $5.5M to Accelerate Drug Discovery with GenAI | What You Should Know: – Converge Bio, a generative AI platform for accelerated drug discovery and development, today announced it has raised $5.5 million in seed funding, led by TLV Partners. – Converge Bio’s platform uses large language mo... |
| 20.11.2024 | Generative AI drug discovery hub Converge Bio raises $5.5M to understand the ‘language of biology’ Your vote of support is important to us and it helps us keep the content FREE. One click below suppor... | Drug discovery startup Converge Bio Inc. said today it has closed on a $5.5 million seed round of funding to help biotech and pharmaceutical companies develop more effective drugs at faster speeds by leveraging generative artificial intelli... |
| - | Converge Bio | “Converge Bio is at the of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLM... |